For the Media
Dr. Soheil Mehinchi is an associate member of Fred Hutch's Clinical Research Division. He is a pediatric hematologist/oncologist who treats children with high-risk leukemias. He is a widely regarded expert in stem cell transplantation for pediatric leukemia patients, management of post-transplant relapse and targeted therapies for acute myeloid leukemia patients. Dr. Meshinchi’s laboratory is focused on the identification and functional evaluation of molecular alterations in leukemias, in order to advance novel “biomarkers” for clinical risk assessment and to be used as therapeutic targets.
Overview of Soheil Meshinchi’s Research Focus
Dr. Meshinchi research is focused on the identification and functional evaluation of molecular alterations in leukemias, in order to advance novel “biomarkers” for clinical risk assessment and to be used as therapeutic targets. He is recognized worldwide as an expert in large-scale studies of the many genes (the genome), “RNA” molecules that are made from genes (the transcriptome), and small chemical changes that can substantially change gene, RNA and protein activities (the epigenome) to promote leukemia formation and progression.
Clinical Research Division
Researchers conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases. Integrating a variety of disciplines, our investigators are continually developing new therapeutic approaches and leading clinical trials that help move discoveries from laboratory to patient. Our pioneering research has saved hundreds of thousands of lives.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.